This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Clinical Trial

. 2002 Aug;2(2):81.

doi: 10.1016/S1533-0028(11)70509-6.

N9741: a phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer

Richard M Goldberg¹

Affiliations

PMID: 12453321
DOI: 10.1016/S1533-0028(11)70509-6

Clinical Trial

N9741: a phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer

Richard M Goldberg. Clin Colorectal Cancer. 2002 Aug.

. 2002 Aug;2(2):81.

doi: 10.1016/S1533-0028(11)70509-6.

Author

Richard M Goldberg¹

Affiliation

¹ Mayo Clinic, Rochester, MN, USA.

PMID: 12453321
DOI: 10.1016/S1533-0028(11)70509-6

No abstract available

PubMed Disclaimer

Similar articles

Oxaliplatin combinations as first-line therapy in advanced colorectal cancer.
[No authors listed] [No authors listed] Clin Colorectal Cancer. 2002 Aug;2(2):78-80. doi: 10.1016/s1533-0028(11)70508-4. Clin Colorectal Cancer. 2002. PMID: 12453320 Clinical Trial. No abstract available.
Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.
Calvo E, Cortés J, Rodríguez J, Fernández-Hidalgo O, Rebollo J, Martín-Algarra S, García-Foncillas J, Martínez-Monge R, de Irala J, Brugarolas A. Calvo E, et al. Clin Colorectal Cancer. 2002 Aug;2(2):104-10. doi: 10.3816/CCC.2002.n.016. Clin Colorectal Cancer. 2002. PMID: 12453325 Clinical Trial.
Irinotecan/5-FU/leucovorin, oxaliplatin/5-FU/leucovorin, and oxaliplatin/irinotecan are each effective in the treatment of 5-FU-resistant advanced colorectal cancer.
Fisher MD. Fisher MD. Clin Colorectal Cancer. 2001 Aug;1(2):85-6. doi: 10.1016/S1533-0028(11)70542-4. Clin Colorectal Cancer. 2001. PMID: 12445365 Review. No abstract available.
Oxaliplatin: a welcome addition to our therapeutic armamentarium.
Chu E. Chu E. Clin Colorectal Cancer. 2002 Aug;2(2):72. doi: 10.3816/CCC.2002.n.013. Clin Colorectal Cancer. 2002. PMID: 12453318 No abstract available.
Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics.
Hwang JJ. Hwang JJ. Oncology (Williston Park). 2004 Dec;18(14 Suppl 14):26-34. Oncology (Williston Park). 2004. PMID: 15685831 Review.

See all similar articles

Cited by

Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.
Rahma OE, Duffy A, Liewehr DJ, Steinberg SM, Greten TF. Rahma OE, et al. Ann Oncol. 2013 Aug;24(8):1972-9. doi: 10.1093/annonc/mdt166. Epub 2013 May 12. Ann Oncol. 2013. PMID: 23670093 Free PMC article. Review.
Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.
Renfro LA, Loupakis F, Adams RA, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Falcone A, Tebbutt NC, Punt CJ, Hecht JR, Bokemeyer C, Van Cutsem E, Goldberg RM, Saltz LB, de Gramont A, Sargent DJ, Lenz HJ. Renfro LA, et al. J Clin Oncol. 2016 Jan 10;34(2):144-50. doi: 10.1200/JCO.2015.61.6441. Epub 2015 Oct 26. J Clin Oncol. 2016. PMID: 26503203 Free PMC article.
Risk factors for oxaliplatin-induced hypersensitivity reaction in patients with colorectal cancer.
Song Q, Cai Y, Guo K, Li M, Yu Z, Tai Q, Zhao Y, Zhu X, Zhang C. Song Q, et al. Am J Transl Res. 2022 Apr 15;14(4):2461-2468. eCollection 2022. Am J Transl Res. 2022. PMID: 35559366 Free PMC article.
Signet-ring cell carcinoma of the colon: A case report of a 9-year-old boy.
Yang S, Liu G, Zheng S, Dong K, Ma Y, Xiao X. Yang S, et al. Oncol Lett. 2015 Sep;10(3):1632-1634. doi: 10.3892/ol.2015.3403. Epub 2015 Jun 22. Oncol Lett. 2015. PMID: 26622723 Free PMC article.
Resistance mechanisms to drug therapy in breast cancer and other solid tumors: An opinion.
Moiseenko F, Volkov N, Bogdanov A, Dubina M, Moiseyenko V. Moiseenko F, et al. F1000Res. 2017 Mar 17;6:288. doi: 10.12688/f1000research.10992.1. eCollection 2017. F1000Res. 2017. PMID: 28751966 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Supplementary concepts

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information